1
|
Olson KM, Hillhouse TM, Burgess GE, West JL, Hallahan JE, Dripps IJ, Ladetto AG, Rice KC, Jutkiewicz EM, Traynor JR. Delta Opioid Receptor-Mediated Antidepressant-Like Effects of Diprenorphine in Mice. J Pharmacol Exp Ther 2023; 384:343-352. [PMID: 36456196 PMCID: PMC9976798 DOI: 10.1124/jpet.122.001182] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2022] [Revised: 11/11/2022] [Accepted: 11/22/2022] [Indexed: 12/03/2022] Open
Abstract
Major depressive disorder is a highly common disorder, with a lifetime prevalence in the United States of approximately 21%. Traditional antidepressant treatments are limited by a delayed onset of action and minimal efficacy in some patients. Ketamine is effective and fast-acting, but there are concerns over its abuse liability. Thus, there is a need for safe, fast-acting antidepressant drugs. The opioid buprenorphine shows promise but also has abuse liability due to its mu-agonist component. Preclinical evidence indicates that the delta-opioid system contributes to mood disorders, and delta-opioid agonists are effective in preclinical models of depression- and anxiety-like states. In this study, we test the hypothesis that the mu-opioid antagonist diprenorphine by virtue of its partial delta opioid agonist activity may offer a beneficial profile for an antidepressant medication without abuse liability. Diprenorphine was confirmed to bind with high affinity to all three opioid receptors, and functional experiments for G protein activation verified diprenorphine to be a partial agonist at delta- and kappa-opioid receptors and a mu-antagonist. Studies in C57BL/6 mice demonstrated that an acute dose of diprenorphine produced antidepressant-like effects in the tail suspension test and the novelty-induced hypophagia test that were inhibited in the presence of the delta-selective antagonist, naltrindole. Diprenorphine did not produce convulsions, a side effect of many delta agonists but rather inhibited convulsions caused by the full delta agonist SNC80; however, diprenorphine did potentiate pentylenetetrazole-induced convulsions. Diprenorphine, and compounds with a similar pharmacological profile, may provide efficient and safe rapidly acting antidepressants. SIGNIFICANCE STATEMENT: The management of major depressive disorder, particularly treatment-resistant depression, is a significant unmet medical need. Here we show that the opioid diprenorphine, a compound with mu-opioid receptor antagonist activity and delta- and kappa-opioid receptor partial agonist activities, has rapid onset antidepressant-like activity in animal models. Diprenorphine and compounds with a similar pharmacological profile to diprenorphine should be explored as novel antidepressant drugs.
Collapse
MESH Headings
- Animals
- Mice
- Analgesics, Opioid/pharmacology
- Antidepressive Agents/pharmacology
- Depressive Disorder, Major
- Diprenorphine/pharmacology
- Mice, Inbred C57BL
- Receptors, Opioid
- Receptors, Opioid, delta/metabolism
- Receptors, Opioid, kappa/metabolism
- Receptors, Opioid, mu/metabolism
- Seizures/chemically induced
Collapse
Affiliation(s)
- Keith M Olson
- Department of Pharmacology and Edward F Domino Research Center (K.M.O., T.M.H., G.E.B., J.L.W., J.E.H., I.J.D., A.G.L., E.M.J., J.R.T.) and Department of Medicinal Chemistry (J.R.T.), University of Michigan, Ann Arbor, Michigan; Department of Psychology, University of Wisconsin Green Bay, Green Bay, Wisconsin (T.M.H.); and Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.)
| | - Todd M Hillhouse
- Department of Pharmacology and Edward F Domino Research Center (K.M.O., T.M.H., G.E.B., J.L.W., J.E.H., I.J.D., A.G.L., E.M.J., J.R.T.) and Department of Medicinal Chemistry (J.R.T.), University of Michigan, Ann Arbor, Michigan; Department of Psychology, University of Wisconsin Green Bay, Green Bay, Wisconsin (T.M.H.); and Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.)
| | - Gwendolyn E Burgess
- Department of Pharmacology and Edward F Domino Research Center (K.M.O., T.M.H., G.E.B., J.L.W., J.E.H., I.J.D., A.G.L., E.M.J., J.R.T.) and Department of Medicinal Chemistry (J.R.T.), University of Michigan, Ann Arbor, Michigan; Department of Psychology, University of Wisconsin Green Bay, Green Bay, Wisconsin (T.M.H.); and Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.)
| | - Joshua L West
- Department of Pharmacology and Edward F Domino Research Center (K.M.O., T.M.H., G.E.B., J.L.W., J.E.H., I.J.D., A.G.L., E.M.J., J.R.T.) and Department of Medicinal Chemistry (J.R.T.), University of Michigan, Ann Arbor, Michigan; Department of Psychology, University of Wisconsin Green Bay, Green Bay, Wisconsin (T.M.H.); and Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.)
| | - James E Hallahan
- Department of Pharmacology and Edward F Domino Research Center (K.M.O., T.M.H., G.E.B., J.L.W., J.E.H., I.J.D., A.G.L., E.M.J., J.R.T.) and Department of Medicinal Chemistry (J.R.T.), University of Michigan, Ann Arbor, Michigan; Department of Psychology, University of Wisconsin Green Bay, Green Bay, Wisconsin (T.M.H.); and Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.)
| | - Isaac J Dripps
- Department of Pharmacology and Edward F Domino Research Center (K.M.O., T.M.H., G.E.B., J.L.W., J.E.H., I.J.D., A.G.L., E.M.J., J.R.T.) and Department of Medicinal Chemistry (J.R.T.), University of Michigan, Ann Arbor, Michigan; Department of Psychology, University of Wisconsin Green Bay, Green Bay, Wisconsin (T.M.H.); and Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.)
| | - Allison G Ladetto
- Department of Pharmacology and Edward F Domino Research Center (K.M.O., T.M.H., G.E.B., J.L.W., J.E.H., I.J.D., A.G.L., E.M.J., J.R.T.) and Department of Medicinal Chemistry (J.R.T.), University of Michigan, Ann Arbor, Michigan; Department of Psychology, University of Wisconsin Green Bay, Green Bay, Wisconsin (T.M.H.); and Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.)
| | - Kenner C Rice
- Department of Pharmacology and Edward F Domino Research Center (K.M.O., T.M.H., G.E.B., J.L.W., J.E.H., I.J.D., A.G.L., E.M.J., J.R.T.) and Department of Medicinal Chemistry (J.R.T.), University of Michigan, Ann Arbor, Michigan; Department of Psychology, University of Wisconsin Green Bay, Green Bay, Wisconsin (T.M.H.); and Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.)
| | - Emily M Jutkiewicz
- Department of Pharmacology and Edward F Domino Research Center (K.M.O., T.M.H., G.E.B., J.L.W., J.E.H., I.J.D., A.G.L., E.M.J., J.R.T.) and Department of Medicinal Chemistry (J.R.T.), University of Michigan, Ann Arbor, Michigan; Department of Psychology, University of Wisconsin Green Bay, Green Bay, Wisconsin (T.M.H.); and Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.)
| | - John R Traynor
- Department of Pharmacology and Edward F Domino Research Center (K.M.O., T.M.H., G.E.B., J.L.W., J.E.H., I.J.D., A.G.L., E.M.J., J.R.T.) and Department of Medicinal Chemistry (J.R.T.), University of Michigan, Ann Arbor, Michigan; Department of Psychology, University of Wisconsin Green Bay, Green Bay, Wisconsin (T.M.H.); and Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.)
| |
Collapse
|
2
|
Stuart T, Jeang WJ, Slivicki RA, Brown BJ, Burton A, Brings VE, Alarcón-Segovia LC, Agyare P, Ruiz S, Tyree A, Pruitt L, Madhvapathy S, Niemiec M, Zhuang J, Krishnan S, Copits BA, Rogers JA, Gereau RW, Samineni VK, Bandodkar AJ, Gutruf P. Wireless, Battery-Free Implants for Electrochemical Catecholamine Sensing and Optogenetic Stimulation. ACS NANO 2023; 17:561-574. [PMID: 36548126 DOI: 10.1021/acsnano.2c09475] [Citation(s) in RCA: 14] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
Neurotransmitters and neuromodulators mediate communication between neurons and other cell types; knowledge of release dynamics is critical to understanding their physiological role in normal and pathological brain function. Investigation into transient neurotransmitter dynamics has largely been hindered due to electrical and material requirements for electrochemical stimulation and recording. Current systems require complex electronics for biasing and amplification and rely on materials that offer limited sensor selectivity and sensitivity. These restrictions result in bulky, tethered, or battery-powered systems impacting behavior and that require constant care of subjects. To overcome these challenges, we demonstrate a fully implantable, wireless, and battery-free platform that enables optogenetic stimulation and electrochemical recording of catecholamine dynamics in real time. The device is nearly 1/10th the size of previously reported examples and includes a probe that relies on a multilayer electrode architecture featuring a microscale light emitting diode (μ-LED) and a carbon nanotube (CNT)-based sensor with sensitivities among the highest recorded in the literature (1264.1 nA μM-1 cm-2). High sensitivity of the probe combined with a center tapped antenna design enables the realization of miniaturized, low power circuits suitable for subdermal implantation even in small animal models such as mice. A series of in vitro and in vivo experiments highlight the sensitivity and selectivity of the platform and demonstrate its capabilities in freely moving, untethered subjects. Specifically, a demonstration of changes in dopamine concentration after optogenetic stimulation of the nucleus accumbens and real-time readout of dopamine levels after opioid and naloxone exposure in freely behaving subjects highlight the experimental paradigms enabled by the platform.
Collapse
Affiliation(s)
- Tucker Stuart
- Department of Biomedical Engineering, University of Arizona, Tucson, Arizona 85721, United States
| | - William J Jeang
- Department of Materials Science and Engineering, Northwestern University, Evanston, Illinois 60201, United States
| | - Richard A Slivicki
- Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States
- Washington University Pain Center, Washington University School of Medicine, St. Louis, Missouri 63110, United States
| | - Bobbie J Brown
- Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States
- Washington University Pain Center, Washington University School of Medicine, St. Louis, Missouri 63110, United States
| | - Alex Burton
- Department of Biomedical Engineering, University of Arizona, Tucson, Arizona 85721, United States
| | - Victoria E Brings
- Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States
- Washington University Pain Center, Washington University School of Medicine, St. Louis, Missouri 63110, United States
| | - Lilian C Alarcón-Segovia
- Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, Illinois 60201, United States
| | - Prophecy Agyare
- Department of Neuroscience, Northwestern University, Evanston, Illinois 60201, United States
| | - Savanna Ruiz
- Department of Materials Science and Engineering, Northwestern University, Evanston, Illinois 60201, United States
| | - Amanda Tyree
- Department of Biomedical Engineering, University of Arizona, Tucson, Arizona 85721, United States
| | - Lindsay Pruitt
- Department of Biomedical Engineering, University of Arizona, Tucson, Arizona 85721, United States
| | - Surabhi Madhvapathy
- Department of Materials Science and Engineering, Northwestern University, Evanston, Illinois 60201, United States
| | - Martin Niemiec
- Department of Biomedical Engineering, University of Arizona, Tucson, Arizona 85721, United States
| | - James Zhuang
- Department of Biomedical Engineering, University of Arizona, Tucson, Arizona 85721, United States
| | - Siddharth Krishnan
- Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, Illinois 60201, United States
| | - Bryan A Copits
- Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States
- Washington University Pain Center, Washington University School of Medicine, St. Louis, Missouri 63110, United States
| | - John A Rogers
- Department of Materials Science and Engineering, Northwestern University, Evanston, Illinois 60201, United States
- Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, Illinois 60201, United States
- Department of Mechanical Engineering, Northwestern University, Evanston, Illinois 60201, United States
- Department of Biomedical Engineering, Northwestern University, Evanston, Illinois 60201, United States
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Evanston, Illinois 60201, United States
- Department of Neurological Surgery, Northwestern University, Evanston, Illinois 60208, United States
- Center for Bio-Integrated Electronics, Northwestern University, Evanston, Illinois 60208, United States
| | - Robert W Gereau
- Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States
- Washington University Pain Center, Washington University School of Medicine, St. Louis, Missouri 63110, United States
- Department of Neuroscience, Washington University, St. Louis, Missouri 63110, United States
- Department of Biomedical Engineering, Washington University, St. Louis, Missouri 63110, United States
| | - Vijay K Samineni
- Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States
- Washington University Pain Center, Washington University School of Medicine, St. Louis, Missouri 63110, United States
| | - Amay J Bandodkar
- Department of Electrical and Computer Engineering, North Carolina State University, Raleigh, North Carolina 27606, United States
- Center for Advanced Self-Powered Systems of Integrated Sensors and Technologies (ASSIST), North Carolina State University, Raleigh, North Carolina 27606, United States
| | - Philipp Gutruf
- Department of Biomedical Engineering, University of Arizona, Tucson, Arizona 85721, United States
- Department of Electrical and Computer Engineering, University of Arizona, Tucson, Arizona 85721, United States
- Bio5 Institute, University of Arizona, Tucson, Arizona 85721, United States
- Neuroscience GIDP, University of Arizona, Tucson, Arizona 85721, United States
| |
Collapse
|
3
|
Kong L, Shu X, Tang S, Ye R, Sun H, Jiang S, Li Z, Chai J, Fang Y, Lan Y, Yu L, Xie Q, Fu W, Wang Y, Li W, Qiu Z, Liu J, Shao L. SLL-627 Is a Highly Selective and Potent κ Opioid Receptor (KOR) Agonist with an Unexpected Nonreduction in Locomotor Activity. J Med Chem 2022; 65:10377-10392. [PMID: 35900351 DOI: 10.1021/acs.jmedchem.2c00014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Undue central nervous system (CNS) side effects including dysphoria and sedation remain to be a challenge for the development of κ opioid receptor (KOR) agonists as effective and safe analgesics. On the basis of our previous work on morphinan-based KOR agonists, a series of 7α-methyl-7β-substituted northebaine derivatives were designed, synthesized, and biologically assayed. Among others, compound 4a (SLL-627) has been identified as a highly selective and potent KOR agonist both in vitro and in vivo, and its molecular basis was also examined and discussed. Besides low liability to conditioned place aversion (CPA) test, treatment of SLL-627 was associated with a nonreduction in locomotor activity, compared to most of the other arylacetamide- or morphinan-based KOR agonists which generally exhibited apparently sedative effects. This unexpected finding provides new insights to dissociate analgesia from sedation for future discovery of innovative KOR agonists.
Collapse
Affiliation(s)
- Linghui Kong
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China
| | - Xuelian Shu
- CAS Key Laboratory of Receptor Research and State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Collaborative Innovation Center for Brain Science, No. 555 Zuchongzhi Road, Shanghai 201203, China.,University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China
| | - Siyuan Tang
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China
| | - Rongrong Ye
- School of Chemical and Environmental Engineering, Shanghai Institute of Technology, No. 100 Haiquan Road, Shanghai 201418, China
| | - Huijiao Sun
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China
| | - Shuang Jiang
- School of Pharmacy, Nanjing University of Chinese Medicine, No. 138, Xianlin Road, Nanjing 210023, China
| | - Zixiang Li
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China
| | - Jingrui Chai
- CAS Key Laboratory of Receptor Research and State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Collaborative Innovation Center for Brain Science, No. 555 Zuchongzhi Road, Shanghai 201203, China
| | - Yun Fang
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China
| | - Yinjie Lan
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China
| | - Linqian Yu
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China
| | - Qiong Xie
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China
| | - Wei Fu
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China
| | - Yujun Wang
- CAS Key Laboratory of Receptor Research and State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Collaborative Innovation Center for Brain Science, No. 555 Zuchongzhi Road, Shanghai 201203, China
| | - Wei Li
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China
| | - Zhuibai Qiu
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China
| | - Jinggen Liu
- CAS Key Laboratory of Receptor Research and State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Collaborative Innovation Center for Brain Science, No. 555 Zuchongzhi Road, Shanghai 201203, China
| | - Liming Shao
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China.,State Key Laboratory of Medical Neurobiology, Fudan University, No. 138 Yixueyuan Road, Shanghai 200032, China
| |
Collapse
|
4
|
Di Ciano P, Le Foll B. Evaluating the Impact of Naltrexone on the Rat Gambling Task to Test Its Predictive Validity for Gambling Disorder. PLoS One 2016; 11:e0155604. [PMID: 27191857 PMCID: PMC4871457 DOI: 10.1371/journal.pone.0155604] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2015] [Accepted: 05/02/2016] [Indexed: 12/27/2022] Open
Abstract
Gambling Disorder has serious consequences and no medications are currently approved for the treatment of this disorder. One factor that may make medication development difficult is the lack of animal models of gambling that would allow for the pre-clinical screening of efficacy. Despite this, there is evidence from clinical trials that opiate antagonists, in particular naltrexone, may be useful in treating gambling disorder. To-date, the effects of naltrexone on pre-clinical models of gambling have not been evaluated. The purpose of the present study was to evaluate the effects of naltrexone in an animal model of gambling, the rat gambling task (rGT), to determine whether this model has some predictive validity. The rGT is a model in which rats are given a choice of making either a response that produces a large reward or a small reward. The larger the reward, the greater the punishment, and thus this task requires that the animal inhibit the ‘tempting’ choice, as the smaller reward option produces overall the most number of rewards per session. People with gambling disorder chose the tempting option more, thus the rGT may provide a model of problem gambling. It was found that naltrexone improved performance on this task in a subset of animals that chose the ‘tempting’, disadvantageous choice, more at baseline. Thus, the results of this study suggest that the rGT should be further investigated as a pre-clinical model of gambling disorder and that further investigation into whether opioid antagonists are effective in treating Gambling Disorder may be warranted.
Collapse
Affiliation(s)
| | - Bernard Le Foll
- Translational Addiction Research Laboratory, CAMH, Toronto, Canada
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada
- Department of Psychiatry, University of Toronto, Toronto, Canada
- Campbell Family Mental Health Research Institute, CAMH, Toronto, Canada
- Ambulatory Care and Structured Treatment Program, CAMH, Toronto, Canada
- Institute of Medical Sciences, University of Toronto, Toronto, Canada
- Department of Family and Community Medicine, University of Toronto, Toronto, Canada
- * E-mail:
| |
Collapse
|
5
|
Ultrasonic communication in rats: Effects of morphine and naloxone on vocal and behavioral responses to playback of 50-kHz vocalizations. Pharmacol Biochem Behav 2009; 94:285-95. [DOI: 10.1016/j.pbb.2009.09.008] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/14/2009] [Revised: 09/05/2009] [Accepted: 09/08/2009] [Indexed: 02/05/2023]
|
6
|
Role of the opioid system in incentive downshift situations. Neurobiol Learn Mem 2009; 92:439-50. [DOI: 10.1016/j.nlm.2009.06.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2009] [Revised: 05/14/2009] [Accepted: 06/10/2009] [Indexed: 11/22/2022]
|
7
|
Olczak M, Duszczyk M, Mierzejewski P, Majewska MD. Neonatal administration of a vaccine preservative, thimerosal, produces lasting impairment of nociception and apparent activation of opioid system in rats. Brain Res 2009; 1301:143-51. [PMID: 19747466 DOI: 10.1016/j.brainres.2009.09.003] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2009] [Revised: 08/27/2009] [Accepted: 09/01/2009] [Indexed: 11/28/2022]
Abstract
Thimerosal (THIM), an organomercury preservative added to many child vaccines is a suspected factor in pathogenesis of neurodevelopmental disorders. We examined the pharmacokinetics of Hg in the brain, liver and kidneys after i.m. THIM injection in suckling rats and we tested THIM effect on nociception. THIM solutions were injected to Wistar and Lewis rats in a vaccination-like mode on PN days 7, 9, 11 and 15 in four equal doses. For Wistar rats these were: 12, 48, 240, 720, 1440, 2160, 3000 microg Hg/kg and for Lewis: 54, 216, 540 and 1080 microg Hg/kg. Pharmacokinetic analysis revealed that Hg from THIM injections accumulates in the rat brain in significant amounts and remains there longer than 30 days after the injection. At the 6th week of age animals were examined for pain sensitivity using the hot plate test. THIM treated rats of both strains and sexes manifested statistically significantly elevated pain threshold (latency for paw licking, jumping) on a hot plate (56 degrees C). Wistar rats were more sensitive to this effect than Lewis rats. Protracted THIM-induced hypoalgesia was reversed by naloxone (5 mg/kg, i.p.) injected before the hot plate test, indicative of involvement of endogenous opioids. This was confirmed by augmented catalepsy after morphine (2.5 mg/kg, s.c.) injection. Acute THIM injection to 6-week-old rats also produced hypoalgesia, but this effect was transient and was gone within 14 days. Present findings show that THIM administration to suckling or adult rats impairs sensitivity to pain, apparently due to activation the endogenous opioid system.
Collapse
Affiliation(s)
- Mieszko Olczak
- Department of Pharmacology and Physiology of the Nervous System, Institute of Psychiatry and Neurology, Warsaw, Poland
| | | | | | | |
Collapse
|
8
|
Häggkvist J, Lindholm S, Franck J. The effect of naltrexone on amphetamine-induced conditioned place preference and locomotor behaviour in the rat. Addict Biol 2009; 14:260-9. [PMID: 19298318 DOI: 10.1111/j.1369-1600.2009.00150.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Whereas amphetamine and other psychostimulants primarily act on the dopamine system, there is also evidence that other neurotransmitter systems, such as the endogenous opioid system, modulate psychostimulant-induced effects. Several studies have investigated the role of opioid antagonists on cocaine-induced conditioned place preference (CPP), but there is limited information about the interaction with amphetamines. The aim of the present study was to investigate the effect of the opioid receptor antagonist, naltrexone (NTX) on the conditioning, expression and reinstatement of amphetamine-induced place preference. In addition, the effect of NTX on locomotor behaviour was measured during all sessions. During training, animals were conditioned with amphetamine (2 mg/kg) to induce place preference. In order to extinguish the conditioned behaviour, animals received saline for 12 days. Reinstatement of CPP was induced by a priming dose of amphetamine (0.5 mg/kg). The interaction of NTX and amphetamine was evaluated using three paradigms of CPP: with NTX (vehicle, 0.3, 1.0 and 3.0 mg/kg) administered either 30 minutes prior to amphetamine conditioning, or 30 minutes before the expression, or 30 minutes before the amphetamine priming to induce reinstatement. Naltrexone had no effect on the conditioning, the expression or the reinstatement induced by a priming dose of amphetamine. Further, NTX by itself did not induce place preference or place aversion. In contrast, NTX significantly attenuated the locomotor response to a priming dose of amphetamine without affecting general locomotor behaviour. The results suggest differences in opioid modulation of amphetamine-induced behaviours in the rat.
Collapse
Affiliation(s)
- Jenny Häggkvist
- Department of Clinical Neuroscience, Division of Psychiatry, Karolinska Institutet, Stockholm, Sweden.
| | | | | |
Collapse
|
9
|
Uhelski ML, Fuchs PN. Naltrexone fails to increase pain affect in response to inflammatory pain in a novel escape/avoidance paradigm. Physiol Behav 2009; 98:263-7. [PMID: 19505486 DOI: 10.1016/j.physbeh.2009.05.019] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2008] [Revised: 04/10/2009] [Accepted: 05/26/2009] [Indexed: 11/30/2022]
Abstract
The non-specific opioid antagonist naltrexone has traditionally been used as treatment for opioid overdose, as well as in research settings as an antagonist to examine opioid and non-opioid mediated analgesia. However, the mechanisms by which this drug operates are not well understood, and its exact effects on sensory and affective pain processes remain uncertain. Various studies have demonstrated that naltrexone behaves in a paradoxical manner, leading to analgesia, no discernable changes, or an increase in pain, depending on the circumstances of the study. This imprecise spectrum of effects leads to difficulty in interpreting results in studies where naltrexone was utilized as an antagonist. Therefore, the purpose of this experiment was to further examine whether naltrexone elicits dose-dependent effects in behavioral tests designed to quantify the sensory and affective components of pain. Naltrexone was not expected to have an effect on carrageenan-induced inflammatory pain in sensory pain measures, but a dose-dependent increase was predicted in behavior related to the affective component of pain. Eighty-eight male Sprague-Dawley rats were used to test these hypotheses by measuring Mechanical Paw Withdrawal Thresholds before and after naltrexone injection and by assessing performance in the Place Escape Avoidance Paradigm test, a novel paradigm to test pain affect, in which naltrexone had not been utilized. The results demonstrated that naltrexone failed to increase place/escape avoidance behavior as anticipated, but rather produced a slight, but non-significant, decrease in escape avoidance behavior. Further research is needed to elucidate the differential effects of naltrexone on various aspects of pain-related behavior.
Collapse
Affiliation(s)
- Megan L Uhelski
- University of Texas at Arlington, Department of Psychology, Box 19528, Arlington, TX 76019, United States
| | | |
Collapse
|
10
|
Pellegrini S, Wood M, Daniel AM, Papini MR. Opioid receptors modulate recovery from consummatory successive negative contrast. Behav Brain Res 2006; 164:239-49. [PMID: 16135386 DOI: 10.1016/j.bbr.2005.06.035] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2005] [Revised: 06/16/2005] [Accepted: 06/16/2005] [Indexed: 01/30/2023]
Abstract
Three experiments explored the role of the opioid system in consummatory successive negative contrast. In Experiment 1, rats treated with the nonspecific opioid-receptor antagonist naloxone (2mg/kg) exhibited increased suppression after a shift from 32% to 6% sucrose solution (32-->6), relative to 6-->6 unshifted controls. A similar but shorter effect was observed with the delta-opioid receptor antagonist naltrindole (1mg/kg). In Experiment 2, naloxone increased suppression after a more conventional 32-->4 sucrose shift. In Experiment 3, rats classified as expressing slow recovery from contrast (after a 32-->4 sucrose downshift) were more sensitive to naloxone in an activity test than fast-recovery rats. Whereas it was previously known that contrast was reduced by the extrinsic administration of opioid agonists, the effects reported here with antagonists provide the first evidence that the opioid system is intrinsically engaged by situations involving surprising reward loss.
Collapse
Affiliation(s)
- Santiago Pellegrini
- Instituto de Biologia y Medicina Experimental and Universidad de Buenos Aires, Argentina
| | | | | | | |
Collapse
|
11
|
Gerrits MAFM, Kuzmin AV, van Ree JM. Reinstatement of cocaine-seeking behavior in rats is attenuated following repeated treatment with the opioid receptor antagonist naltrexone. Eur Neuropsychopharmacol 2005; 15:297-303. [PMID: 15820419 DOI: 10.1016/j.euroneuro.2004.11.004] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2004] [Revised: 11/11/2004] [Accepted: 11/25/2004] [Indexed: 11/21/2022]
Abstract
In the present study we show that the endogenous opioid systems play a modulating role in cocaine-induced reinstatement of drug-seeking behavior in rats. We investigated the effect of blockade of opioid receptors on reinstatement of cocaine-seeking behavior by cocaine priming. Drug-naive rats were allowed to initiate self-administration behavior of cocaine (30 and 60 mug per infusion, i.v.) for 5 consecutive daily sessions, and after a 5-day extinction period during which the rats did not receive cocaine, a test for cocaine-induced (1 mg/kg, i.v.) reinstatement followed. The effect of cocaine priming was tested on days 1, 3, and 5 after extinction, while on days 2 and 4 the animals received saline priming. Before each daily reinstatement test, different groups of animals received an injection with the opioid receptor antagonist naltrexone (3 mg/kg, s.c.) or with placebo. We observed that cocaine readily reinstated extinguished responding in the rats, and that this reinstatement responding did not change over the consecutive reinstatement tests. Pretreatment with naltrexone progressively attenuates the cocaine-induced reinstatement, with a significant reduction on days 3 and 5 of reinstatement testing. Discriminative lever-pressing (active versus inactive lever) during reinstatement phase, however, remains present in animals treated with naltrexone. This implies that repeated opioid receptor blockade progressively attenuates cocaine-induced drug-seeking behavior in abstained animals, but this cannot simply be attributed to extinction of cocaine-seeking behavior.
Collapse
Affiliation(s)
- Mirjam A F M Gerrits
- Department of Pharmacology and Anatomy, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands.
| | | | | |
Collapse
|
12
|
Febo M, Jiménez-Rivera CA, Segarra AC. Estrogen and opioids interact to modulate the locomotor response to cocaine in the female rat. Brain Res 2002; 943:151-61. [PMID: 12088849 DOI: 10.1016/s0006-8993(02)02748-8] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Estrogen is known to modulate the behavioral response to cocaine; however the mechanisms by which this is accomplished is unknown. In this study we examine one possible candidate, the endogenous opioid system. Adult Sprague-Dawley rats were ovariectomized (OVX), half received Silastic implants with estradiol benzoate (OVX-EB), the other half received empty implants (OVX). After 1 week, spontaneous locomotor and stereotyped activity was measured for 60 min using an automated system. On day 2, locomotor activity was recorded for 30 min. Rats were injected with saline (SAL) or naloxone (NAL) (2 mg/kg, i.p.) and activity measured for the next 20 min. Each of these groups were further subdivided, one that received a saline injection (SAL) and another that received a cocaine injection (COC) (15 mg/kg, i.p.). Locomotor and stereotyped activities were recorded for 60 min. This resulted in the following injection groups: SAL-SAL, NAL-SAL, SAL-COC and NAL-COC. During habituation, OVX rats displayed an overall higher level of activity than OVX-EB rats. Similar to what is observed in males, naloxone significantly reduced locomotion and stereotyped behavior but only in OVX rats. Estrogen administration to OVX rats abolished the effect of naloxone. Surprisingly, when naloxone was administered prior to cocaine, an increase in cocaine-induced locomotor and stereotyped activity was observed, but only in OVX-EB rats. These results indicate that opioid modulation of cocaine-induced locomotor and stereotype activity in the female differs from that reported in the male. In addition in the female, the effect of opioids on cocaine-induced locomotor behavior is dependent on plasma levels of estrogen.
Collapse
Affiliation(s)
- Marcelo Febo
- Department of Physiology, School of Medicine, University of Puerto Rico, PO Box 365067, San Juan, PR 00936, USA
| | | | | |
Collapse
|
13
|
Sisti HM, Lewis MJ. Naloxone suppression and morphine enhancement of voluntary wheel-running activity in rats. Pharmacol Biochem Behav 2001; 70:359-65. [PMID: 11701208 DOI: 10.1016/s0091-3057(01)00624-4] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
This study examines the effects of the opioid receptor antagonist, naloxone, and the agonist, morphine, on voluntary wheel-running activity (WR) in rats. Male Sprague-Dawley rats were given 1-h access to a running wheel under non-deprived conditions. Naloxone injections (1.0, 0.5, or 0.25 mg/kg, ip), administered immediately before access to running wheels, dose-dependently suppressed WR. In another experiment, subjects were given 6-h access to running wheels under nondeprived conditions for 5 consecutive days. Morphine injections (2.0 mg/kg, sc) were found to increase WR after an initial suppression. These data demonstrate that naloxone inhibits WR, while morphine both suppresses and enhances WR depending on time and dose. These are in agreement with data on other behaviors that indicate that endogenous opioid systems play a major role in the mediation of motivational behaviors.
Collapse
Affiliation(s)
- H M Sisti
- Department of Psychology, Temple University, Philadelphia, PA 19122, USA.
| | | |
Collapse
|
14
|
Goodwin FL, Campisi M, Babinska I, Amit Z. Effects of naltrexone on the intake of ethanol and flavored solutions in rats. Alcohol 2001; 25:9-19. [PMID: 11668013 DOI: 10.1016/s0741-8329(01)00163-x] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
It has been suggested that the endogenous opioid system may mediate the intake of preferred fluids, perhaps through an attenuation of reinforcement properties causing a subsequent shift in palatability. The purpose of the present study was to investigate the effects of the nonspecific opiate antagonist naltrexone on the intake of 10% ethanol, 0.1% saccharin, 0.0006% quinine, 0.4% saccharin + 10% ethanol, and 0.4% saccharin + 0.04% quinine solutions. Fluid intake was measured in male Long-Evans and Wistar rats under 24-h continuous and 30-min limited-fluid-access drinking paradigms. All rats received injections of naltrexone hydrochloride (10 mg/kg, i.p.) for 5 days after baseline intake measures and were monitored for a further 5 days (after-treatment phase). Results indicated that naltrexone did not affect intake of any solution when fluids were available over 24 h. However, under limited-access conditions, naltrexone caused a decrease in the intake of all fluids except quinine in both rat strains. On the basis of these findings, it is possible that the effects of this dose of naltrexone were not due to any true conditioning effect on the reinforcement properties of ethanol, but perhaps to some nonspecific effect of the drug, such as an alteration in palatability or an attenuation of locomotor activity. As well, due to the inconsistent results in fluid intake across drinking paradigms, the present findings do not provide evidence for an effective role for opiate mediation in ethanol intake as well as any ethanol-sweet fluid intake interactions.
Collapse
Affiliation(s)
- F L Goodwin
- Centre for Studies in Behavioural Neurobiology, Concordia University, 1455 de Maisonneuve Blvd. W. H-1013, Montreal, Quebec, Canada H3G 1M8.
| | | | | | | |
Collapse
|
15
|
Crisanti KC, Fewell JE. Naloxone does not alter the "regulated" decrease in core temperature during hypoxemia in guinea pigs. J Appl Physiol (1985) 1998; 85:1150-9. [PMID: 9729594 DOI: 10.1152/jappl.1998.85.3.1150] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
In newborns and adults of a number of species, exposure to acute hypoxemia produces a "regulated" decrease in core temperature, the mechanism of which is unknown. The present experiments were carried out in chronically instrumented newborn (5-10 days of age; n = 59) and older (25-30 days of age; n = 61) guinea pigs to test the hypothesis that the endogenous opioids mediate this regulated decrease in core temperature. During an experiment, core temperature, oxygen consumption, and selected ambient temperature were measured in a thermocline (linear temperature gradient of 10-40 degreesC) during a control period of normoxemia, an experimental period of normoxemia or hypoxemia (inspired oxygen fraction 0.10), and during a recovery period of normoxemia following an intraperitoneal injection of naloxone hydrochloride (a nonspecific opioid antagonist; 1, 2, or 4 mg/kg) or vehicle. Naloxone did not significantly alter basal core temperature or the core temperature response to acute hypoxemia in newborn or older guinea pigs. Naloxone did, however, decrease basal oxygen consumption in newborn and older guinea pigs and altered the thermoregulatory effector mechanism used to decrease core temperature during hypoxemia in the newborn guinea pigs. Our data do not support the hypothesis that the endogenous opioids mediate the regulated decrease in core temperature that occurs in newborn and older guinea pigs during exposure to acute hypoxemia.
Collapse
Affiliation(s)
- K C Crisanti
- Department of Physiology and Biophysics, The University of Calgary Health Sciences Centre, Calgary, Alberta T2N 4N1, Canada
| | | |
Collapse
|
16
|
Feigenbaum JJ, Howard SG. The effect of naloxone on spontaneous and evoked dopamine release in the central and peripheral nervous systems. Life Sci 1996; 59:2009-19. [PMID: 8950303 DOI: 10.1016/s0024-3205(96)00399-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
A number of studies have reported that the opiate antagonist naloxone (NX) inhibits behaviors dependent upon central dopamine (DA) release. However, equally compelling evidence from other studies suggests that NX excites a facilitatory effect. The present review was undertaken to resolve the issue by critically evaluating the effects of NX on DA release; the substrate subserving these behaviors. Included are studies reporting an effect of NX on spontaneous as well as drug altered DA release in various central regions. In the preponderant majority of these studies, NX was found to significantly enhance DA release in the virtually every major DA pathway, irrespective of whether DA release was initially stimulated or inhibited by various agents. It is concluded that NX most probably enhances behaviors induced by DA release, especially when administered in low, specific doses. Studies finding an inhibitory effect of NX on such behaviors may inadvertently produce conditions which mask the stimulatory effects of NX on DA release-dependent behaviors.
Collapse
Affiliation(s)
- J J Feigenbaum
- American Institute of Biotechnology, Department of Research and Development, Elk Grove Village, IL 60007, USA
| | | |
Collapse
|
17
|
Jones DN, Holtzman SG. Influence of naloxone upon motor activity induced by psychomotor stimulant drugs. Psychopharmacology (Berl) 1994; 114:215-24. [PMID: 7838910 DOI: 10.1007/bf02244839] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Naloxone, an opioid receptor antagonist, attenuates a wide range of behavioral effects of d-amphetamine, such as the stimulation of motor activity. To investigate the pharmacological selectivity of the naloxone/amphetamine interaction, we assessed the effects of naloxone (5.0 mg/kg SC) upon motor activity induced in rats by a range of psychomotor stimulant drugs with a mechanism of action either similar to or different from that of d-amphetamine. Each of the drugs tested caused dose-dependent increases in both gross and fine activity. Naloxone attenuated the gross but not the fine activity response to d- and l-amphetamine, but had no influence upon the other catecholamine-releasing drugs, methamphetamine and phendimetrazine. In contrast, naloxone increased the gross but not the fine activity response to the catecholamine uptake inhibitors cocaine and mazindol, but had no effects upon the motor response to methylphenidate. The responses to other stimulant drugs (apomorphine, caffeine, scopolamine) were unaffected by naloxone pretreatment. The present findings extend the range of conditions under which naloxone and, by inference, endogenous opioid systems, modulate the behavioral response to psychomotor stimulants. However, the differential effects of naloxone upon the motor response to individual stimulant drugs support previous suggestions of fundamental differences in mechanisms of action among these compounds.
Collapse
Affiliation(s)
- D N Jones
- Department of Pharmacology, Emory University School of Medicine, Atlanta, GA 30322
| | | |
Collapse
|
18
|
Abstract
Naloxone, a nonspecific opioid antagonist, has been found to decrease the activity and social behavior of rats tested in pairs but the effects on individual locomotor activity have been equivocal. In the present study, groups of male Long-Evans hooded rats received naloxone (1 or 4 mg/kg, IP) or vehicle alone (isotonic saline) 30 min prior to testing sessions. Individual locomotor activity was measured in two activity boxes (41-cm3) equipped with two infrared photobeams using daily 30-min testing sessions for 5 consecutive days. Following a 1-week washout period (no testing), activity and social attraction (paired distance and contact) were examined in pairs of rats from each group using daily 15-min testing sessions for 4 consecutive days. Locomotor activity and its habituation were not significantly affected by naloxone in rats tested individually. However, both doses of naloxone significantly reduced paired locomotor activity compared to the control group. Measures of social attraction were not significantly affected by naloxone. The present findings suggest that naloxone does not produce nonspecific depressant effects on activity but rather may antagonize opioid release in situational contexts of high arousal (e.g., social activity) with consequent reduction of activity.
Collapse
Affiliation(s)
- C P Dokla
- Department of Psychology, Saint Anselm College, Manchester, NH 03102-1310
| |
Collapse
|
19
|
Cazala P, David V. Differential effects of naloxone on approach and escape responses induced by electrical stimulation of the lateral hypothalamus or the mesencephalic central gray area in mice. Pharmacol Biochem Behav 1991; 40:323-7. [PMID: 1805235 DOI: 10.1016/0091-3057(91)90561-f] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
BALB/c mice implanted with a bipolar electrode were trained in a shuttle-box to initiate and to terminate a continuous electrical stimulation applied in the lateral hypothalamus (LH) or in the mesencephalic central gray area (CG). Following stabilization of the baseline response latencies, the subjects were subcutaneously injected with isotonic NaCl or with naloxone HCl (0.5, 2 or 10 mg/kg) 15 min or 45 min before a test session. In LH-stimulated animals no modification of the behavioral responses was observed after injection of 0.5 mg/kg of naloxone. The 2 mg/kg dose increased the value of escape latency (ON time) but had no effect on approach latency (OFF time). The 10 mg/kg dose also increased ON time. At this dose, an increase of OFF time was simultaneously observed but only 15 min after the injection. In CG-stimulated mice an increase of OFF time and a reduction of ON time were recorded 15 min after the injection of 0.5 mg/kg. Only the reduction of ON time was detected for the 45-min delay. The 2 mg and 10 mg/kg doses simultaneously increased OFF time and reduced ON time for the two delays. These results demonstrate 1) that the effects of naloxone on self-stimulation varied as a function of the structure considered 2) that the predominant characteristic of the considered structure (essentially "rewarding" as the LH or "aversive" as the CG) governs the modulations induced by naloxone.
Collapse
Affiliation(s)
- P Cazala
- Laboratoire de Psychophysiologie, URA CNRS 339, Université de Bordeaux I, UFR de Biologie, Talence, France
| | | |
Collapse
|
20
|
Hoffman DC, West TE, Wise RA. Ventral pallidal microinjections of receptor-selective opioid agonists produce differential effects on circling and locomotor activity in rats. Brain Res 1991; 550:205-12. [PMID: 1653084 DOI: 10.1016/0006-8993(91)91319-v] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Locomotor activity was investigated following microinjections of receptor-selective opioid agonists into the ventral pallidum (VP) of rats. In Expt. 1, male Long-Evans rats were treated with unilateral microinjections of the mu agonist [D-Ala2-MePhe4, Gly-ol5]-enkephalin (DAGO), the delta agonist [D-Pen2, D-Pen5]-enkephalin (DPDPE) or the kappa agonist U50,488H, and the rate and duration of circling behaviour were measured. DAGO (0.01, 0.1, 1.0 nmol) produced a dose-dependent increase in contralateral circling; pretreatment with 1.0 mg/kg naltrexone blocked the circling induced by the highest dose. The behavioral effect was largest when injections were targeted at the VP rather than structures dorsal to the VP. In contast to DAGO, intrapallidal DPDPE (0.01, 0.1, 1.0, 10.0 nmol) produced a slight increase in contralateral circling only at the highest dose and U50, 488H (0.01, 0.1, 1.0, 10.0 nmol) produced no effect. In Expt. 2, the effects of bilateral injections of DAGO, DPDPE and U50,488H were tested in photocell activity boxes. DAGO produced a dose-dependent increase in locomotor activity and this increase was decreased by 1.0 mg/kg naltrexone. A slight increase in activity was observed with the highest dose of DPDPE, and a slight decrease was observed with the highest dose of U50,488H. These findings confirm that opiate actions in the VP contribute to opiate-induced locomotion and suggest that mu and to some extent delta receptors are involved in this behavior.
Collapse
MESH Headings
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
- Analgesics/pharmacology
- Animals
- Dose-Response Relationship, Drug
- Enkephalin, Ala(2)-MePhe(4)-Gly(5)-
- Enkephalin, D-Penicillamine (2,5)-
- Enkephalins/administration & dosage
- Enkephalins/pharmacology
- Functional Laterality
- Globus Pallidus/drug effects
- Globus Pallidus/physiology
- Male
- Microinjections
- Motor Activity/drug effects
- Naltrexone/pharmacology
- Pyrrolidines/administration & dosage
- Pyrrolidines/pharmacology
- Rats
- Receptors, Opioid/drug effects
- Receptors, Opioid/physiology
- Receptors, Opioid, delta
- Receptors, Opioid, kappa
- Receptors, Opioid, mu
- Stereotyped Behavior/drug effects
- Time Factors
Collapse
Affiliation(s)
- D C Hoffman
- Department of Psychology, Concordia University, Montreal, Canada
| | | | | |
Collapse
|
21
|
Pinheiro AD, Wright DC. Naloxone eliminates passive avoidance retention deficits produced by pretest exposure to novelty in rats. BEHAVIORAL AND NEURAL BIOLOGY 1991; 55:270-88. [PMID: 1647763 DOI: 10.1016/0163-1047(91)90621-v] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Pretest exposure to novelty or injections of beta-endorphin can enhance passive avoidance (PA) retention (e.g., Izquierdo & McGaugh, 1985). Enhanced retention may result from a "state-dependent" match between the CNS state during test and the novelty-induced beta-endorphin state that is obtained during training in a novel apparatus. Our Experiment 1 suggests that, unlike PA, Pavlovian fear conditioning in a conditioned lick suppression (CLS) paradigm may be beta-endorphin "state-independent." Rats were given one tone-shock pairing in a novel environment. Baseline lick rates and CLS tested 48 h later in a familiar environment were not affected by pretest exposure to novelty and/or injections of 3.33 mg/kg naloxone HCl. In Experiment 2, the same rats were PA trained/tested in a new apparatus. Saline or naloxone injections and various exposure (novel, familiar, none) conditions preceded (1h) the 24-h retention test. Pretest exposure to novelty reduced retention and naloxone eliminated that deficit. In Experiment 3, naive rats given pretest exposure to novelty also showed a PA retention deficit. The results of Experiments 2 and 3 may complement rather than contradict previous findings. Pretest induction of a beta-endorphin state by novelty may either enhance state-dependent retrieval of a "weak" memory trace or make a "strong/well consolidated" training memory more vulnerable to retroactive interference from "new learning" during the pretest exposure period.
Collapse
Affiliation(s)
- A D Pinheiro
- Department of Psychology, University of Missouri, Columbia 65211
| | | |
Collapse
|
22
|
Abstract
The mu opioid receptor ligand [D-Ala2, NMePhe4, Gly-ol5]enkephalin (DAGO) and delta opioid receptor ligand [D-Pen2,D-Pen5]enkephalin (DPDPE) show similar specificity in competition binding studies in whole brain homogenate in rat and mouse. However, in saturation studies, the density and affinity of DPDPE binding sites were substantially greater in the mouse. There was no difference between the mouse and rat in the density and affinity of DAGO sites. Results from dose-response studies for analgesia using the same ligands administered i.c.v. in both species paralleled the binding studies. DAGO was approximately 2 times more potent in the mouse compared to the rat; while DPDPE was more than 15 times more potent in the mouse. Thus, binding capacity and affinity differences appear to be related to the functional potency of the mu and delta ligands in the two species. These results suggest that the difference in potency of DPDPE between rat and mouse is related to the differences in brain delta opioid receptors.
Collapse
MESH Headings
- Analgesics/administration & dosage
- Analgesics/pharmacology
- Animals
- Enkephalin, Ala(2)-MePhe(4)-Gly(5)-
- Enkephalin, D-Penicillamine (2,5)-
- Enkephalins/administration & dosage
- Enkephalins/pharmacology
- Injections, Intraventricular
- Kinetics
- Male
- Mice
- Pain Measurement
- Rats
- Rats, Inbred Strains
- Reaction Time/drug effects
- Receptors, Opioid/metabolism
- Receptors, Opioid/physiology
- Receptors, Opioid, mu
- Receptors, sigma
- Species Specificity
Collapse
Affiliation(s)
- B C Yoburn
- Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John's University, Queens, NY 11439
| | | | | |
Collapse
|
23
|
Trujillo KA, Belluzzi JD, Stein L. Naloxone blockade of amphetamine place preference conditioning. Psychopharmacology (Berl) 1991; 104:265-74. [PMID: 1876671 DOI: 10.1007/bf02244190] [Citation(s) in RCA: 54] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Amphetamine and naloxone were examined in place conditioning, in order to study possible interactions between endogenous opioids and catecholamines in reinforcement. After initial preferences were determined, animals were conditioned with amphetamine alone (1.0 mg/kg SC), naloxone alone (0.02, 0.2 or 2.0 mg/kg SC) or combinations of amphetamine plus naloxone. A reliable, long-lasting preference for the compartment associated with amphetamine was observed, reflecting the reinforcing properties of this drug. No preference or aversion was observed in animals that received saline in both compartments. Naloxone (0.02, 0.2 and 2.0 mg/kg) produced a dose-dependent place aversion; while the lowest dose had effects similar to saline, the higher doses produced significant place aversions. Naloxone, at all three doses examined, prevented the ability of amphetamine to produce a place preference. Thus, the lowest dose of naloxone, having no effects alone in place conditioning was still able to block the reinforcing effects of amphetamine. These results suggest that the reinforcing effects of amphetamine are dependent on activation of opiate receptors, and provide further evidence that interactions between endogenous opioids and catecholamines may be important in reinforcement.
Collapse
Affiliation(s)
- K A Trujillo
- Department of Pharmacology, University of California, Irvine 92717
| | | | | |
Collapse
|
24
|
Touzani K, Akarid K, Velley L. Modulation of saccharin preference by morphine and naloxone: inversion of drug effects as a function of saccharin concentration. Pharmacol Biochem Behav 1991; 38:37-41. [PMID: 2017452 DOI: 10.1016/0091-3057(91)90586-q] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The aim of the present study was to verify and extend a recent, isolated observation showing that, in rats, a moderate dose of morphine may induce either an increase or a decrease in preference for saccharin, the direction of the response depending apparently on the concentration of the sweetener. Two experiments were performed successively. First, we showed that the preference threshold for saccharin (0.3 mM, two-bottle procedure) of rats placed on a schedule of restricted water access was significantly decreased following injection of 1 mg/kg of morphine. In the second experiment, three groups of naive rats were submitted to the preference test but the concentration of saccharin solution was different for each group, namely 0.3, 1 and 1.7 mM. After stabilization of the baseline responses the effect of morphine (1 mg/kg) was tested in each of the 3 groups. As observed previously morphine decreased the preference of the rats tested with the 0.3 mM solution, but markedly increased the preference of the two other groups tested with the 1 and 1.7 mM solutions respectively. The effects of low doses of naloxone (0.01, 0.1 and 1 mg/kg) were then tested on the same groups of rats with the same saccharin concentrations. The 0.01 mg/kg dose of the antagonist increased the preference for the groups of rats tested with the 0.3 and 1 mM solutions. The other two doses of naloxone decreased saccharin intake whatever the saccharin concentration used. It is suggested that these apparently paradoxical effects of morphine and naloxone could result either from the stimulation of opioid autoreceptors or from the differential stimulation of different opioid receptor subtypes.
Collapse
Affiliation(s)
- K Touzani
- Laboratoire de Psychophysiologie URA CNRS No. 339, Université de Bordeaux I, Talence, France
| | | | | |
Collapse
|
25
|
Trujillo KA, Belluzzi JD, Stein L. Opiate antagonists and self-stimulation: extinction-like response patterns suggest selective reward deficit. Brain Res 1989; 492:15-28. [PMID: 2752295 DOI: 10.1016/0006-8993(89)90884-6] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The present study investigated the response decrement patterns produced by opiate antagonists on intracranial self-stimulation behavior, in order to determine if these drugs affect the reinforcement value of the stimulation or interfere with the ability of the animal to respond. Male rats lever-pressed in 60-min sessions on a continuous reinforcement schedule for self-stimulation of the nucleus accumbens. Naloxone (2.0 and 20 mg/kg) and naltrexone (2.0 and 20 mg/kg) suppressed self-stimulation only after a significant delay, in an extinction-like response decrement pattern, mimicking the effects of reductions in current intensity (75% and 50% of baseline). The increasing behavioral effects characteristic of the extinction pattern were observed despite the fact that testing began after the time point at which maximal suppression of self-stimulation occurs with these drugs, and when brain concentrations of these drugs were declining. Since normal responding was observed for several minutes after the beginning of the session, the results may explain why long sessions are necessary to observe suppression of self-stimulation by opiate antagonists. The extinction-like pattern produced by these drugs suggests that opiate antagonists suppress self-stimulation by reducing the reinforcement value of the stimulation, rather than by interfering with the ability of the animal to respond. These findings are consistent with a role for endogenous opioid peptides in brain stimulation reward.
Collapse
Affiliation(s)
- K A Trujillo
- Department of Pharmacology, College of Medicine, University of California, Irvine 92717
| | | | | |
Collapse
|
26
|
Trujillo KA, Belluzzi JD, Stein L. Effects of opiate antagonists and their quaternary analogues on nucleus accumbens self-stimulation. Behav Brain Res 1989; 33:181-8. [PMID: 2548531 DOI: 10.1016/s0166-4328(89)80049-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Naloxone and naltrexone were compared with their quaternary analogues naloxone methobromide and naltrexone methobromide for efficacy in suppressing intracranial self-stimulation behavior. These quaternary analogues effectively block opiate receptors in the periphery, but since they do not readily cross the blood-brain barrier they have little effect on central receptors. Rats with electrodes in the nucleus accumbens were trained to self-stimulate in daily 60-min sessions. Naloxone (0.2, 2.0 and 20 mg/kg) and naltrexone (20 mg/kg) potently suppressed self-stimulation behavior. In contrast, neither naloxone methobromide (0.2 and 20 mg/kg) nor naltrexone methobromide (20mg/kg) had any significant effects on this behavior. These results suggest that blockade of peripheral opiate receptors alone is insufficient to suppress self-stimulation, and therefore support the idea that opiate antagonists suppress self-stimulation by blockade of central receptors that mediate reinforcement.
Collapse
Affiliation(s)
- K A Trujillo
- Department of Pharmacology, College of Medicine, University of California, Irvine 92717
| | | | | |
Collapse
|
27
|
Cooper SJ, Turkish S. Effects of naltrexone on food preference and concurrent behavioral responses in food-deprived rats. Pharmacol Biochem Behav 1989; 33:17-20. [PMID: 2780774 DOI: 10.1016/0091-3057(89)90422-x] [Citation(s) in RCA: 53] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Naltrexone (0.05-5.0 mg/kg, SC) was administered to food-deprived rats prior to a 15-min food-preference test. Total food intake and feeding duration was reduced following administration of the opiate antagonist. However, while naltrexone reduced the consumption of the initially-preferred chocolate-coated cookies, the ingestion of the nonpreferred standard laboratory chow pellets was significantly enhanced. These data cannot be explained in terms of a general anorexic effect and nonspecific suppression of feeding responses. Instead, they indicate that naltrexone reduced preference for the highly palatable cookies, so that a feeding response to the chow pellets emerged. Under the conditions of test-familiarity, naltrexone did not reduce grooming, locomotion or rearing duration. An increase in locomotion may have been secondary to the reduction in feeding. The results agree with previous data from animal and human studies in suggesting that endogenous opioid peptide activity is involved in the palatability of preferred foods.
Collapse
Affiliation(s)
- S J Cooper
- School of Psychology, University of Birmingham, United Kingdom
| | | |
Collapse
|
28
|
Trujillo KA, Belluzzi JD, Stein L. Naloxone suppression of self-stimulation is independent of response difficulty. Pharmacol Biochem Behav 1989; 33:147-55. [PMID: 2675125 DOI: 10.1016/0091-3057(89)90444-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The action of the opiate antagonist naloxone on relatively easy (nose-poke) and relatively difficult (lever-press) self-stimulation behaviors was compared, in order to determine if opiate antagonists suppress self-stimulation by interfering with the ability of the animal to respond, or by reducing the reinforcement value of the stimulation. Naloxone (0.2, 2.0 and 20 mg/kg) significantly suppressed both nose-poking and lever-pressing self-stimulation rates, and the degree of suppression was virtually identical for both tasks at all doses examined. If naloxone had interfered with the ability of the animal to respond, then lever-pressing--which requires more motor output than nose-poking--should have been more suppressed than nose-poking. The results suggest that opiate antagonists do not interfere with the ability of the animal to respond, and are therefore consistent with the hypothesis that these drugs reduce the reinforcement value of the stimulation.
Collapse
Affiliation(s)
- K A Trujillo
- Department of Pharmacology, College of Medicine, University of California, Irvine 92717
| | | | | |
Collapse
|
29
|
Abstract
This review examines the literature on the effects of opiate antagonists on brain stimulation (ICSS) reward. Antagonists should have predictable effects if endogenous opioids modulate ICSS. Naloxone is the antagonist most often used, and it has produced inconsistent results in some ICSS paradigms. When schedules of intermittent reinforcement are used, however, naloxone reliably reduces the rate of responding. It reverses the effects of opiate agonists on ICSS behavior, and it also attenuates the effects of psychomotor stimulants, such as amphetamine. The results produced by naloxone are consistent with a modulatory effect of endogenous opioid systems on reward, and suggest that the opiate and dopamine systems together exert significant control over ICSS. Further research is needed to characterize better the actions of the antagonists on ICSS behavior, and productive research directions are proposed. Data obtained in future studies might suggest how the endogenous opioid systems modulate both natural and brain stimulation reward.
Collapse
Affiliation(s)
- G J Schaefer
- Department of Psychiatry, Emory University School of Medicine, Georgia Mental Health Institute, Atlanta 30306
| |
Collapse
|
30
|
Schaefer GJ, Michael RP. Naloxone and diprenorphine reduce responding for brain self-stimulation in a fixed-ratio schedule in rats. Pharmacol Biochem Behav 1988; 29:209-12. [PMID: 3353428 DOI: 10.1016/0091-3057(88)90299-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Rats were implanted with bipolar stimulating electrodes in the midbrain-central gray area (MID-CG) and trained to lever-press for intracranial self-stimulation (ICSS) on a continuous reinforcement schedule (CRF). When behavior was stable, animals were tested in 30 min ICSS sessions following the administration of either naloxone or diprenorphine, both over the dose-range 0.001-10 mg/kg, or with vehicle. Following testing on the CRF schedule, animals were re-trained on a fixed-ratio:30 (FR:30) schedule. When behavior had again stabilized, testing with naloxone, diprenorphine and vehicle was repeated. In the CRF tests, neither naloxone nor diprenorphine had any effects on response rates over the 10,000-fold dose-range used. In the FR:30 tests, however, both drugs significantly reduced response rates at the 10 mg/kg dose, and the reduction produced by naloxone was significantly greater than that produce by diprenorphine. These results suggested that diprenorphine is qualitatively similar to naloxone in altering the rate of responding maintained by ICSS, but is less potent than the prototypical opioid antagonist in this paradigm.
Collapse
Affiliation(s)
- G J Schaefer
- Department of Psychiatry, Emory University School of Medicine, Georgia Mental Health Institute, Atlanta 30306
| | | |
Collapse
|
31
|
Andrews JS, Holtzman SG. Effects of naloxone and diprenorphine on amphetamine-stimulated behavior in guinea pigs and rats. Neuropharmacology 1987; 26:1115-20. [PMID: 3658118 DOI: 10.1016/0028-3908(87)90256-5] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Amphetamine (0.1-10 mg/kg), naloxone (0.1-10 mg/kg) and diprenorphine (0.03-10 mg/kg) were studied for their ability to modulate locomotor behavior in the guinea pig. Naloxone, administered alone, caused a non-significant decrease in locomotor activity and had a similar non-significant effect on amphetamine-stimulated activity. Diprenorphine induced a significant suppression of locomotor activity, the magnitude of which was inversely related to dose: smaller doses of diprenorphine caused a greater suppression of locomotor activity than larger doses. Two doses of diprenorphine (0.1 and 1.0 mg/kg) were tested in combination with amphetamine in the guinea pig. They significantly reduced amphetamine-stimulated behavior and were equipotent in this regard. In contrast, diprenorphine had no effect on amphetamine-stimulated activity in rats. However, in keeping with other reports, naloxone (10 mg/kg) significantly reduced amphetamine-stimulated behavior. The differences in the actions of diprenorphine and naloxone on the behavior of guinea pigs and rats may reflect a different underlying distribution of subtypes of opioid receptor in the two species.
Collapse
Affiliation(s)
- J S Andrews
- Department of Pharmacology, Emory University School of Medicine, Atlanta, GA 30322
| | | |
Collapse
|
32
|
Abstract
When naloxone is administered during morphine elicited hyperactivity, hyperactivity is reversed and hypoactivity occurs in its place. The present experiment tested the hypothesis that this effect is the result of morphine induced supersensitivity to naloxone. Two groups of hamsters received equivalent pretreatment with 15 mg/kg morphine (Groups M/M and M/S) for three days while a third group received saline (Group S/S). During subsequent testing one group received a morphine injection (Group M/M) while the others received saline (Groups M/S and S/S) before being placed in running wheels for a three hour session. Two hours later half the animals in each group received an injection of 0.4 mg/kg naloxone and half received saline. Naloxone produced hypoactivity in animals running under the influence of morphine (Group M/M), but neither in those with an equivalent history of morphine pre-treatment (Group M/S), nor in saline controls (Group S/S). These results are inconsistent with the hypothesis under test, but congruent with a modified dual-action hypothesis.
Collapse
|
33
|
Andrews JS, Holtzman SG. The interaction of d-amphetamine and naloxone differs for rats trained on separate fixed-interval or fixed-ratio schedules of reinforcement. Pharmacol Biochem Behav 1987; 26:167-71. [PMID: 3562487 DOI: 10.1016/0091-3057(87)90550-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The effects of d-amphetamine and naloxone were investigated using two groups of rats trained on either an FR30 or F12 schedule of reinforcement. Amphetamine (0.1-1.0 mg/kg), and naloxone (1.0 and 10 mg/kg) administered separately reduced responding on the FR procedure in a dose-dependent manner. The combined administration of naloxone with amphetamine had an additive suppressive effect on responding. The same doses of amphetamine and naloxone, when given separately, did not significantly depress responding in the FI procedures. However, naloxone/amphetamine combinations produced a marked inhibition of lever-pressing. Naloxone did not alter the characteristic pattern of responding engendered by amphetamine in this schedule, as measured by the quarter-life and Index of Curvature. It appears that the type of procedure used is a critical factor in demonstrating the effects of naloxone on behavior, and the nature of naloxone/amphetamine interactions.
Collapse
|
34
|
Stevens KE, Mickley GA, McDermott LJ. Brain areas involved in production of morphine-induced locomotor hyperactivity of the C57B1/6J mouse. Pharmacol Biochem Behav 1986; 24:1739-47. [PMID: 3737639 DOI: 10.1016/0091-3057(86)90514-9] [Citation(s) in RCA: 31] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Previous studies reveal a dose-dependent increase in locomotor activity of the C57B1/6J mouse after administration of morphine or amphetamine. Concurrent partial lesions of both the dorsomedial caudate and lateral septal nuclei resulted in a significant decrease in morphine-induced, but not amphetamine-induced, hyperactivity. Concurrent partial lesions of the nucleus accumbens and stria terminalis produced only a nonsignificant decrease in the morphine-induced hyperactivity. Lesions of the individual brain structures did not significantly affect the morphine-induced locomotor hyperactivity. Microinjections of the opiate antagonist naloxone into discrete portions of the caudate and septal nuclei produced suppression of the morphine-induced hyperactivity response without affecting the hyperactivity caused by amphetamine injections. Only a slight suppression of morphine-induced locomotion was produced when naloxone was injected into the nucleus accumbens and stria terminalis. These data suggest that portions of the caudate and septum may be involved in the mediation of morphine-induced hyperactivity in the C57B1/6J mouse.
Collapse
|
35
|
Reymann KG, Wulcko S, Ott T, Matthies H. Opioid-receptor blockade reduces nose-poke self-stimulation derived from medial entorhinal cortex. Pharmacol Biochem Behav 1986; 24:439-43. [PMID: 3010334 DOI: 10.1016/0091-3057(86)90538-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Rats were trained to nose-poke for intracranial self-stimulation (SS) with electrodes unilaterally implanted in the medial entorhinal cortex. The acute effects of naloxone (NX; 0.1-10 mg/kg, IP) on a continuous reinforcement schedule were determined. Reductions in the self-stimulation rates occurred only at moderate doses (median of individual changes = -36% at 1 and 5 mg/kg), whereas the high dose (10 mg/kg) was ineffective. None of the doses influenced operant behavior. These results are consistent with the hypothesis that endogenous opioid-opiate receptor mechanisms play a modulatory role in SS reward. Considering that NX was administered systemically the action of the drug on reinforcement levels may be mediated by a site distinct from the locus of stimulation.
Collapse
|
36
|
McAllister KH, Berry MS, Brain PF. Substrate soiled by an unfamiliar conspecific modifies opioid activity in mice placed in novel environments. Physiol Behav 1985; 35:465-71. [PMID: 4070416 DOI: 10.1016/0031-9384(85)90324-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Naloxone induces behavioural changes in rodents exposed to novel environments, indicating the involvement of endogenous opioid mechanisms in these situations. The present study investigated whether soiled sawdust substrate from the cage of an unfamiliar, isolated, male conspecific modifies the effect of naloxone (0.5 or 12.5 mg/kg) upon behaviour of mice in an open field test situation. There was little difference between the effects of naloxone upon the frequency of acts or postures shown in the soiled and unsoiled environments. Cluster analysis of the activities according to their position and frequency in behavioural sequences, revealed variations in behavioural organisation in these two situations in control animals, and differential responses to naloxone administration. The data are discussed in terms of an involvement in behaviour of opioid mechanisms which can be modified by non-painful, biologically-relevant, aversive stimuli such as unfamiliar, conspecific-soiled substrates.
Collapse
|
37
|
Mayer AD, Faris PL, Komisaruk BR, Rosenblatt JS. Opiate antagonism reduces placentophagia and pup cleaning by parturient rats. Pharmacol Biochem Behav 1985; 22:1035-44. [PMID: 2991949 DOI: 10.1016/0091-3057(85)90314-4] [Citation(s) in RCA: 31] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Since endogenous opiate mechanisms are activated during parturition, the present study examined in rats the effects of opiate antagonism on maternal care during and shortly after parturition. Endogenous opiate mechanisms were blocked in late pregnant rats by (1) naltrexone pellet implants (Experiment 1); (2) acute naloxone injections of 10 mg/kg (Experiment 2) or 0.1 mg/kg (Experiment 7); or (3) induction of opiate tolerance (Experiment 3). All methods resulted in a significant decrease in placentophagia and/or in cleaning pups of umbilical cords and birth fluids (Experiment 6). Other aspects of maternal care appeared relatively unaffected and 24 hr pup survival rats were lowered only by induction of morphine tolerance (probably via its effects on the young). In nonpregnant females, naloxone produced a small but significant decrease in placentophagia (Experiment 4) whereas morphine-tolerant nonpregnant females consumed placentas as readily as controls (Experiment 5). Thus the inhibition of placentophagia produced by opiate antagonism may be specific to conditions associated with parturition. These findings suggest that endogenous opiates support placenta eating and pup cleaning during and immediately after birth. Mediation may be via opiate effects on ingestive behavior, and/or via a reduction in the stress of parturition which otherwise can interfere with the female's ability to perform these tasks.
Collapse
|
38
|
McAllister KH, Berry MS. Naloxone does not affect tube restraint-induced target biting by male Swiss mice. Behav Processes 1985; 10:429-36. [DOI: 10.1016/0376-6357(85)90042-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/08/1984] [Indexed: 10/27/2022]
|
39
|
DeRossett SE, Holtzman SG. Effects of opiate antagonists and putative kappa agonists on unpunished and punished operant behavior in the rat. Psychopharmacology (Berl) 1985; 86:386-91. [PMID: 2994149 DOI: 10.1007/bf00427896] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The effects of naloxone and diprenorphine, opiate antagonists with different receptor-binding properties, and the putative kappa-receptor agonists, ketocyclazocine and ethylketocyclazocine (EKC), were studied on food-reinforced responding in rats. Behavior was maintained under a multiple-component 1-min variable-interval schedule in which 12-min periods of unpunished responding alternated with 4-min periods in which each response was punished by a brief electric footshock. Daily sessions were 1 h. Naloxone (0.01-10 mg/kg) decreased unpunished responding only slightly; punished responding was decreased significantly to 66% of control by 10 mg/kg. Diprenorphine (0.01-10 mg/kg) did not affect unpunished responding and increased punished responding dose-dependently to as much as 190% of control. EKC (0.01-1.0 mg/kg) decreased unpunished and punished responding dose-dependently and comparably, whereas ketocyclazocine (0.01-1.0 mg/kg) decreased unpunished responding but did not significantly affect punished responding. Diprenorphine was more potent than naloxone in blocking the decreases in responding produced by the kappa agonists. Differences in the behavioral effects of naloxone and diprenorphine appear to reflect the different receptor-binding properties of the two opiate antagonists.
Collapse
|
40
|
Myers WD, Ng KT, Singer G. Effects of naloxone and buprenorphine on intravenous acetaldehyde self-injection in rats. Physiol Behav 1984; 33:449-55. [PMID: 6514833 DOI: 10.1016/0031-9384(84)90168-9] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Rats can be induced to self-inject acetaldehyde under an appropriate operant conditioning schedule. The narcotic antagonist naloxone (30 mg/kg) is shown to produce a decrease in schedule-induced acetaldehyde self-injection, but was without effect on both barpress responding and spontaneous activity in rats tested individually for fine, gross and total activity. On the other hand buprenorphine (0.3 and 3 mg/kg), the mixed agonist-antagonist derived from the opium alkaloid thebaine, also produced a significant decrease in acetaldehyde self-injection. However, a significant effect of buprenorphine on barpressing in otherwise drug naive rats indicated that this finding should not be dissociated from a possible involvement of buprenorphine on motor responding. While the findings are consistent with the hypothesis of opiate involvement in acetaldehyde self-administration, caution must be exercised when drawing conclusions about the participation of endogenous opiates in acetaldehyde-mediated behavior.
Collapse
|
41
|
Abstract
Locomotor activity of golden Syrian hamsters was investigated in three experiments. In Experiment 1, running wheel activity of male and female hamsters was compared under the following conditions: no injection, saline injection, morphine injection (15 mg/kg) and naltrexone injection (1 mg/kg). During two hour test sessions, females maintained high levels of activity, whereas males slowed down considerably during the second hour. The difference between males and females was evident under all conditions except following morphine which produced a biphasic time-effect pattern in both sexes. Naltrexone, however, had no detectable effects on either males or females. Experiment 2 investigated the effects of four doses of naltrexone (0.3, 1, 3, 10 mg/kg) on hamster locomotion. Results indicated that none of the doses tested had an effect. Experiment 3 demonstrated that a 1 mg/kg dose of naltrexone antagonizes two of morphine's (15 mg/kg) effects on activity. First, naltrexone partially blocked morphine elicited sedation. Second, naltrexone blocked the increase in activity that characterizes recovery from morphine.
Collapse
|
42
|
Holtzman SG. Complete, reversible, drug-specific tolerance to stimulation of locomotor activity by caffeine. Life Sci 1983; 33:779-87. [PMID: 6888193 DOI: 10.1016/0024-3205(83)90784-1] [Citation(s) in RCA: 72] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The development of tolerance to caffeine-induced stimulation of locomotor activity was evaluated in rats maintained chronically on average daily doses of 160 mg/kg or more of caffeine by the method of scheduled access to drinking water containing the drug. Dose-response curves were determined for caffeine (6.25-100 mg/kg) and d-amphetamine (0.39-6.4 mg/kg) during chronic drug treatment. In addition, the caffeine curve was redetermined 2-3 weeks after removal of the drug from the drinking water. A control group that had scheduled access to drug-free tap water was also tested. Caffeine produced dose-related increases in the locomotor activity of the controls but failed to modify locomotor activity of the chronic caffeine group. In contrast, d-amphetamine increased locomotor activity of both groups comparably. Spontaneous locomotor of the chronic caffeine group was reduced significantly for 4 days after drug-free tap water was substituted for the caffeine solution. The return of spontaneous locomotor activity to baseline values was associated with restored sensitivity to caffeine-induced stimulation of locomotor activity. Thus, chronic administration of caffeine to rats results in the development of tolerance to caffeine-induced stimulation of locomotor activity that is virtually complete, pharmacologically specific, and fully reversible when drug treatment is stopped. Decreases in spontaneous locomotor activity after abrupt termination of chronic caffeine administration follow a time course consistent with a drug withdrawal syndrome.
Collapse
|
43
|
Abstract
This article is the fifth installment in an annual series of reviews of successive year's research dealing with the endogenous opiate peptides. Due to the continuing massive increase in the number of studies in this field, it has become impossible to continue comprehensive reviews of all aspects of this work. As a result we have decided that beginning this year the coverage will be abbreviated to emphasize non-analgesic and behavioral work. The specific areas discussed include stress, tolerance and dependence, consummatory responses, alcohol consumption, schizophrenia and emotional disorders, learning and memory, cardiovascular responses, respiratory effects, thermoregulatory effects, neurological deficits and other disorders, activity, and other, miscellaneous behaviors. As in previous years, we have attempted a relatively comprehensive review of the subjects covered only for the previous year and have not made an attempt to evaluate their contributions relative to those of past years.
Collapse
|